SEC Filings | Landos Biopharma

Filing date	Form	Description	View
04/28/22	DEFA14A	Additional proxy soliciting materials - definitive	0001193125-22-127644.pdf 0001193125-22-127644.rtf View HTML
07/24/20	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-20-007158.pdf 4.4 MB 0000950123-20-007158.rtf 0000950123-20-007158.xls View HTML
09/01/20	DRS/A	Amendment to a previously filed DRS	0000950123-20-009456.pdf 5.4 MB 0000950123-20-009456.rtf 0000950123-20-009456.xls View HTML
11/30/20	DRS/A	Amendment to a previously filed DRS	0000950123-20-012413.pdf 6.6 MB 0000950123-20-012413.rtf 0000950123-20-012413.xls View HTML
02/03/21	EFFECT	EFFECT	9999999995-21-000415.pdf 72.7 KB 9999999995-21-000415.rtf 9999999995-21-000415.xls View HTML
08/15/22	EFFECT	EFFECT	9999999995-22-002380.pdf 9999999995-22-002380.rtf 9999999995-22-002380.xls View HTML
01/13/21	S-1	Registration statement for face-amount certificate companies	0001193125-21-008210.pdf 8 MB 0001193125-21-008210.rtf 0001193125-21-008210.xls View HTML
01/28/21	S-1/A	Amended Registration statement for face-amount certificate companies	0001193125-21-020102.pdf 8.5 MB 0001193125-21-020102.rtf 0001193125-21-020102.xls View HTML
02/01/21	S-1/A	Amended Registration statement for face-amount certificate companies	0001193125-21-024746.pdf 6.7 MB 0001193125-21-024746.rtf 0001193125-21-024746.xls View HTML
03/24/22	S-3	Simplified registration form	0001193125-22-084033.pdf 0001193125-22-084033.rtf 0001193125-22-084033.xls View HTML

Data provided by Kaleidoscope.